Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 479 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 Research shows one size doesn’t fit all for cervical screening in... May 17, 2021 Managing Cancer Pain: Are Better Approaches on the Horizon? January 23, 2019 Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... July 9, 2024 Load more HOT NEWS How MRI add-ons could accelerate the development of new treatments FDA Approves HPV Tests That Allow for Self-Collection in a Health... FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients...
